These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 18633127

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
    Chang HW, Lin YW, Lin MH, Lan YC, Wang RY.
    PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
    [Abstract] [Full Text] [Related]

  • 27. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D, Sripradit S, Angthararak S.
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [Abstract] [Full Text] [Related]

  • 28. [How to select and use urate lowering agents for hyperuricemia].
    Yamanaka H.
    Nihon Rinsho; 1996 Dec; 54(12):3261-5. PubMed ID: 8976102
    [Abstract] [Full Text] [Related]

  • 29. Up-titration of allopurinol in patients with gout.
    Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, Riches PL, Ralston SH, MacDonald TM, FAST study group.
    Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169
    [Abstract] [Full Text] [Related]

  • 30. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
    Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT.
    Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
    [Abstract] [Full Text] [Related]

  • 31. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [Abstract] [Full Text] [Related]

  • 32. Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study.
    Kang EH, Shin A, Park CS, Lee EB, Lee YJ, Curhan G, Choi HK.
    Rheumatology (Oxford); 2024 Sep 01; 63(9):2433-2441. PubMed ID: 38733596
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
    Perez-Ruiz F, Hernandez-Baldizon S, Herrero-Beites AM, Gonzalez-Gay MA.
    Arthritis Care Res (Hoboken); 2010 Sep 01; 62(9):1299-305. PubMed ID: 20506124
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S.
    Semin Arthritis Rheum; 2015 Oct 01; 45(2):174-83. PubMed ID: 26190562
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.